Sana Biotechnology (NASDAQ:SANA) Raised to Outperform at Citizens Jmp

Citizens Jmp upgraded shares of Sana Biotechnology (NASDAQ:SANA) from a market perform rating to an outperform rating in a research report released on Tuesday, MarketBeat Ratings reports. The firm currently has $5.00 price target on the stock.

Other research analysts have also issued reports about the stock. HC Wainwright raised their price objective on shares of Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, Jefferies Financial Group started coverage on shares of Sana Biotechnology in a research note on Friday, March 14th. They issued a “buy” rating and a $7.00 price objective on the stock. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.80.

Sana Biotechnology Trading Down 3.4 %

NASDAQ:SANA opened at $2.26 on Tuesday. The stock has a market capitalization of $504.59 million, a price-to-earnings ratio of -1.61 and a beta of 1.63. The firm has a fifty day simple moving average of $2.98 and a two-hundred day simple moving average of $3.19. Sana Biotechnology has a 12 month low of $1.52 and a 12 month high of $10.50.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. Equities analysts predict that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the completion of the transaction, the insider now owns 4,541,511 shares in the company, valued at $29,474,406.39. This trade represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 31.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Sana Biotechnology

Hedge funds have recently bought and sold shares of the company. FMR LLC lifted its position in Sana Biotechnology by 16.3% during the third quarter. FMR LLC now owns 31,609,175 shares of the company’s stock valued at $131,494,000 after purchasing an additional 4,438,949 shares during the last quarter. Boxer Capital Management LLC bought a new stake in Sana Biotechnology during the fourth quarter valued at approximately $2,518,000. Corient Private Wealth LLC lifted its position in Sana Biotechnology by 161.7% during the fourth quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company’s stock valued at $1,928,000 after purchasing an additional 730,699 shares during the last quarter. Millennium Management LLC lifted its position in Sana Biotechnology by 604.8% during the fourth quarter. Millennium Management LLC now owns 728,901 shares of the company’s stock valued at $1,188,000 after purchasing an additional 625,481 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in Sana Biotechnology by 44.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company’s stock valued at $2,538,000 after purchasing an additional 478,596 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.